These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37641582)

  • 21. Safety of donating multiple products in a single apheresis collection: are we expecting too much?
    Strauss RG
    J Clin Apher; 2003; 18(3):135-40. PubMed ID: 14569607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse reactions to whole blood donation and plasmapheresis.
    Grindon AJ
    Crit Rev Clin Lab Sci; 1982; 17(1):51-75. PubMed ID: 6749431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA).
    Schulzki T; Seidel K; Storch H; Karges H; Kiessig S; Schneider S; Taborski U; Wolter K; Steppat D; Behm E; Zeisner M; Hellstern P;
    Vox Sang; 2006 Aug; 91(2):162-73. PubMed ID: 16907878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of plasmapheresis on blood pressure in voluntary plasma donors.
    Rosa-Bray M; Wisdom C; Marier JF; Mouksassi MS; Wada S
    Vox Sang; 2015 Jan; 108(1):11-7. PubMed ID: 25169580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The determinants of donor safety and product quality in optimization of apheresis granulocyte harvest: An experience from a tertiary care oncology centre in India.
    Ojha S; Poojary M; Mokalikar U; Sumathi SH; Kumar A; Gupta AM; Saha S
    Transfus Apher Sci; 2022 Oct; 61(5):103445. PubMed ID: 35450807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors.
    Yuan S; Ziman A; Smeltzer B; Lu Q; Goldfinger D
    Transfusion; 2010 Feb; 50(2):478-86. PubMed ID: 19843285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of citrate and citrate infusion rate during donor plasmaphereses.
    Evers J; Taborski U
    J Clin Apher; 2016 Feb; 31(1):59-62. PubMed ID: 26011445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence of relative iron deficiency in platelet- and plasma-pheresis donors correlates with donation frequency.
    Li H; Condon F; Kessler D; Nandi V; Rebosa M; Westerman M; Shaz BH; Ginzburg Y
    J Clin Apher; 2016 Dec; 31(6):551-558. PubMed ID: 26915437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and protection of plasma donors: A scoping review and evidence gap map.
    Schroyens N; D'aes T; De Buck E; Mikkelsen S; Tiberghien P; van den Hurk K; Erikstrup C; Compernolle V; Van Remoortel H
    Vox Sang; 2024 Feb; 119(2):110-120. PubMed ID: 37814964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Source Plasma Donation: The Experience of the Iranian Blood Transfusion Organization.
    Mohammadi S; Aghabozorg F; Balagholi S; Ferdowsi S; Sharifi S; Eshghi P
    Int J Hematol Oncol Stem Cell Res; 2022 Jul; 16(3):151-156. PubMed ID: 36694705
    [No Abstract]   [Full Text] [Related]  

  • 32. Complications of blood donation reported to haemovigilance systems: analysis of eleven years of international surveillance.
    Wiersum-Osselton JC; Politis C; Richardson C; Goto N; Grouzi E; Marano G; Land KJ
    Vox Sang; 2021 Jul; 116(6):628-636. PubMed ID: 33278040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved donor safety in high-volume apheresis collections.
    Vassallo RR; Bravo MD; Kamel H
    Transfusion; 2017 Feb; 57(2):319-324. PubMed ID: 27861957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent source plasma donors are not at risk of iron depletion: the Ferritin Levels in Plasma Donor (FLIPD) study.
    Schreiber GB; Brinser R; Rosa-Bray M; Yu ZF; Simon T
    Transfusion; 2018 Apr; 58(4):951-959. PubMed ID: 29520799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events and retention of donors of double red cell units by apheresis.
    Keshelashvili K; O'meara A; Stern M; Jirout Z; Pehlic V; Holbro A; Buser A; Sigle J; Infanti L
    Blood Transfus; 2016 Sep; 14(5):391-9. PubMed ID: 27136442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apheresis donor safety--changes in humoral and cellular immunity.
    Strauss RG
    J Clin Apher; 1984; 2(1):68-80. PubMed ID: 6536660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanical donor plasmapheresis using the Haemonetics Ultralite plasma collection system. 1. Collection of fresh plasma].
    Matthes G; Pawlow I; Richter E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):343-8. PubMed ID: 2475417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical considerations for planning a therapeutic apheresis procedure.
    Shelat SG
    Am J Med; 2010 Sep; 123(9):777-84. PubMed ID: 20541168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three different schedules of low-density lipoprotein apheresis compared with plasmapheresis in patients with homozygous familial hypercholesterolemia.
    Berger GM; Firth JC; Jacobs P; Wood L; Marais AD; Horak A
    Am J Med; 1990 Feb; 88(2):94-100. PubMed ID: 2105647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulation, bleeding, and clotting at donor plasmapheresis.
    Evers J; Taborski U
    J Clin Apher; 2018 Aug; 33(4):538-540. PubMed ID: 29575131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.